Nordic Nanovector to merge with APIM Therapeutics
Nordic Nanovector ASA and all shareholders of APIM Therapeutics ("APIM"), a privately held, clinical-stage cancer-focused biotechnology company, announce that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction
Subject to completion of the Agreement, Nordic Nanovector will purchase shares in APIM, and become the parent entity of APIM. The Agreement follows the review that Nordic Nanovector conducted, in conjunction with Carnegie Investment Bank, to optimise shareholder value following its decision to discontinue the PARADIGME study for Nordic Nanovector's lead asset Betalutin.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins